Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Non-Current Liabilities: 2012-2025

Historic Total Non-Current Liabilities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $215.8 million.

  • Enanta Pharmaceuticals' Total Non-Current Liabilities fell 12.86% to $215.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.8 million, marking a year-over-year decrease of 12.86%. This contributed to the annual value of $215.8 million for FY2025, which is 12.86% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Total Non-Current Liabilities of $215.8 million as of FY2025, which was down 12.86% from $247.6 million recorded in FY2024.
  • Enanta Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $247.6 million for FY2024, and its period low was $38.8 million during FY2021.
  • For the 3-year period, Enanta Pharmaceuticals' Total Non-Current Liabilities averaged around $236.1 million, with its median value being $244.9 million (2023).
  • In the last 5 years, Enanta Pharmaceuticals' Total Non-Current Liabilities skyrocketed by 356.67% in 2023 and then fell by 12.86% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $38.8 million in 2021, then spiked by 38.19% to $53.6 million in 2022, then skyrocketed by 356.67% to $244.9 million in 2023, then rose by 1.11% to $247.6 million in 2024, then fell by 12.86% to $215.8 million in 2025.